Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials

NCT06029465 | Not Yet Recruiting

• 1 other identifier: 84447609
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

The study seeks to delve into the firsthand experiences of patients diagnosed with rhabdomyosarcoma who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all rhabdomyosarcoma patients as well as those in under-represented demographic groups.

Conditions

Rhabdomyosarcoma

Keywords

Rhabdomyosarcoma

Outcome Measures

Primary Outcomes (2)

• Number of rhabdomyosarcoma patients who decide to enroll in a clinical trial

  3 months

• Rate of rhabdomyosarcoma patients who remain in clinical trial to trial completion

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with rhabdomyosarcoma who are actively considering enrolling in an observational clinical study for said condition, but have not yet completed enrollment and randomization phases.

You may qualify if:

• Diagnosis of rhabdomyosarcoma
• Considered reliable, able to understand, and willing to perform all study procedures
• Signed Written Informed Consent

You may not qualify if:

• Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug
• Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
• Any serious and/or unstable pre-existing medical disorders

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

Location

Related Publications (3)

• Sparber-Sauer M, Ferrari A, Kosztyla D, Ladenstein R, Cecchetto G, Kazanowska B, Scarzello G, Ljungman G, Milano GM, Niggli F, Alaggio R, Vokuhl C, Casanova M, Klingebiel T, Zin A, Koscielniak E, Bisogno G. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. Pediatr Blood Cancer. 2022 Sep;69(9):e29691. doi: 10.1002/pbc.29691. Epub 2022 Apr 19.

  PMID: 35441463 BACKGROUND

• Saulnier-Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK. A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clin Cancer Res. 2022 Sep 15;28(18):3950-3957. doi: 10.1158/1078-0432.CCR-22-1169.

  PMID: 35833850 BACKGROUND

• Leiner J, Le Loarer F. The current landscape of rhabdomyosarcomas: an update. Virchows Arch. 2020 Jan;476(1):97-108. doi: 10.1007/s00428-019-02676-9. Epub 2019 Nov 6.

  PMID: 31696361 BACKGROUND

MeSH Terms

Conditions

Rhabdomyosarcoma

Condition Hierarchy (Ancestors)

Myosarcoma; Neoplasms, Muscle Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

(415) 900-4227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 1, 2023
• First Posted: September 8, 2023
• Study Start: October 1, 2024
• Primary Completion: October 1, 2025
• Study Completion (Estimated): October 1, 2026
• Last Updated: September 8, 2023

Record last verified: 2023-09

Locations

US (1)